Black Diamond Therapeutics receives FDA IND clearance for BDTX-1535; Phase 1 start in Q1 2022

Black Diamond Therapeutics, Inc.

FDA allowed IND application for BDTX-1535 on January 10, 2022.
Phase 1 study of BDTX-1535 to begin in Q1 2022.
Company expects to provide a clinical update in the second half of 2023.

item 8.01

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-002587

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.